Andrew Lawrence Feldhaus, Lynnwood, WA (US); Leon Garcia-Martinez, Woodinville, WA (US); Benjamin H. Dutzar, Seattle, WA (US); Daniel S. Allison, Lake Forest Park, WA (US); Katie Olson Anderson, Kirkland, WA (US); Ethan Wayne Ojala, Snohomish, WA (US); Pei Fan, Bothell, WA (US); Charlie Karasek, Seattle, WA (US); Jenny Mulligan, Lake Forest Park, WA (US); Michelle Scalley-Kim, Seattle, WA (US); Erica Stewart, St. Shoreline, WA (US); Jeffrey T. L. Smith, Bellevue, WA (US); and John Latham, Seattle, WA (US)
Assigned to H. LUNDBECK A/S, Valby (DK)
Filed by H. LUNDBECK A/S., Valby (DK)
Filed on Jun. 27, 2022, as Appl. No. 17/850,135.
Application 17/850,135 is a division of application No. 16/779,889, filed on Feb. 3, 2020, granted, now 11,427,631.
Application 16/779,889 is a division of application No. 15/613,414, filed on Jun. 5, 2017, granted, now 10,550,180.
Application 15/613,414 is a division of application No. 14/627,458, filed on Feb. 20, 2015, granted, now 9,688,754.
Claims priority of provisional application 62/094,763, filed on Dec. 19, 2014.
Claims priority of provisional application 61/948,920, filed on Mar. 6, 2014.
Claims priority of provisional application 61/948,922, filed on Mar. 6, 2014.
Claims priority of provisional application 61/942,416, filed on Feb. 20, 2014.
Claims priority of provisional application 61/942,280, filed on Feb. 20, 2014.
Prior Publication US 2023/0174641 A1, Jun. 8, 2023
1. A humanized or chimerized anti-human adrenocorticotrophic hormone (ACTH) antibody or antibody fragment comprising a variable heavy chain polypeptide comprising the CDR1, CDR2 and CDR3 respectively of SEQ ID NO: 204, 206 and 208; and a variable light chain polypeptide comprising the CDR1, CDR2 and CDR3 respectively of SEQ ID NO: 224, 226 and 228.